Next Article in Journal
Procainamide for the Rapid Suppression of Premature Ventricular Contractions: An (Almost) Forgotten Tool in the Cardiologist’s Armamentarium
Previous Article in Journal
Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 11
Issue 2
10.3390/diagnostics11020355
Review Report
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Assessment of PSIM (Prostatic Systemic Inflammatory Markers) Score in Predicting Pathologic Features at Robotic Radical Prostatectomy in Patients with Low-Risk Prostate Cancer Who Met the Inclusion Criteria for Active Surveillance

Diagnostics 2021, 11(2), 355; https://doi.org/10.3390/diagnostics11020355
by Matteo Ferro 1,*, Gennaro Musi 1, Deliu Victor Matei 1, Alessandro Francesco Mistretta 1, Stefano Luzzago 1, Gabriele Cozzi 1, Roberto Bianchi 1, Ettore Di Trapani 1, Antonio Cioffi 1, Giuseppe Lucarelli 2, Gian Maria Busetto 3, Francesco Del Giudice 4, Giorgio Ivan Russo 5, Marina Di Mauro 5, Angelo Porreca 6, Giuseppe Renne 7, Michele Catellani 1, Danilo Bottero 1, Antonio Brescia 1, Giovanni Cordima 1 and Ottavio de Cobelli 1,8add Show full author list remove Hide full author list
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Diagnostics 2021, 11(2), 355; https://doi.org/10.3390/diagnostics11020355
Submission received: 7 February 2021 / Revised: 18 February 2021 / Accepted: 19 February 2021 / Published: 20 February 2021
(This article belongs to the Section Pathology and Molecular Diagnostics)

Round 1

Reviewer 1 Report

This study was reported the utility of PSIM in patients with low-risk prostate cancer who underwent RARP. The reviewer would like to suggest some critiques as follows.

 

Major revision

  1. The reviewer think that the Title is unclear. What is “pathological significant disease”?
  2. The authors should follow the journal style indicated in the instructions, especially the Reference sections.
  3. The authors should spell out csPCa, RP, NLR, PLR, LMR, and PSA at the Abstract.
  4. On page 2, line 33; ofPCa → of PCa
  5. On page 3, line 31, “At multivariate…..wasn’t found” is unclear. The reviewer think that “ On multivariate analysis, there were no significant differences …” is correct.

Author Response

Dear reviewer thank you for your work.

We modified the text as follow:

1) title has been changed

2) reference section has been adapted to journal style

3) in the abstract we added required abbreviations

4) corrected

5) corrected

Reviewer 2 Report

An interesting manuscript  showing an assessment of PSIM score in patients with low risk prostate cancer. In my opinion, It exist many scoring systems which were applied for estimate diagnostic tool in patients with cancerous ethiologies. I think that clearly depends on the patients group selection . Authors well documented use the PSIM score in patients with low risk prostate cancer, nevertheless, My question which authors need to discuss is  if the course will be applicable for for patients with pT0-PT1 stage  and if is in literature described some corellation with biochemical parmetres including PHI etc. After discussing and comment this minor suggestions, I approve the manuscript for publication.

Author Response

Dear reviewer, thank you for you work.

Regarding your request about applicability of our model to pT0-pT1 patients it wasn't used with these patient, even in literature there isn't anything at this regard. On the other side we added a sentence (in red) and two references regarding correlation with PHI and biochemical parameters.

Back to TopTop